integrated filling
RPPINFRA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved standalone and consolidated audited financial results for Q4 and FY ended 31 March 2025. FY25 revenue from operations rose to Rs. 1,431.55 crore from Rs. 1,332.39 crore (up ~7.4%), but net profit was nearly flat at Rs. 65.47 crore versus Rs. 65.52 crore in FY24, reflecting margin compression. Q4 FY25 was notably weak with net profit of Rs. 12.56 crore compared to Rs. 22.04 crore in Q4 FY24. The board recommended a modest final dividend of Rs. 0.50 per share (5%) subject to shareholder approval. Material related party transactions worth about Rs. 664.32 crore with Repplen Projects (where directors are related) and Rs. 412.81 crore via RPP-Satyamoorthy JV were approved. Operating cash flow fell sharply from Rs. 51.58 crore to Rs. 1.22 crore. A Rs. 254 crore CPCL contract was prematurely terminated, causing a Rs. 15 crore gross loss.
Mixed picture for shareholders: revenue growth was decent but profitability and operating cash generation weakened, and the Rs. 1,000+ crore worth of related party transactions involving director-linked entities may raise governance questions. The small 5% dividend and weak cash flow limit near-term upside, though the unmodified audit opinion and strong order pipeline (Rs. 1,000+ crore new work) provide some support.